메뉴 건너뛰기




Volumn 36, Issue 2, 2012, Pages 313-317

Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: A randomized open-label trial

Author keywords

Olanzapine; Oral standard tablet; Orally disintegrating tablet; Schizophrenia; Weight gain

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CHOLESTEROL; CLOMIPRAMINE; FLUVOXAMINE; GLUCOSE; HALOPERIDOL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM SALT; MILNACIPRAN; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; TRIACYLGLYCEROL; VALPROIC ACID;

EID: 84855347421     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.11.004     Document Type: Article
Times cited : (7)

References (23)
  • 1
    • 1842844950 scopus 로고    scopus 로고
    • Consensus development conference on antipsychotic drugs and obesity and diabetes
    • American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, North American Association for the Study of ObesityNorth American Association for the Study of Obesity
    • Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004, 65:267-272. American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, North American Association for the Study of ObesityNorth American Association for the Study of Obesity.
    • (2004) J Clin Psychiatry , vol.65 , pp. 267-272
  • 2
    • 33846596713 scopus 로고    scopus 로고
    • Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients
    • Arranz B., San L., Duenas R.M., Centeno M., Ramirez N., Salavert J., et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol Clin Exp 2007, 22:11-15.
    • (2007) Hum Psychopharmacol Clin Exp , vol.22 , pp. 11-15
    • Arranz, B.1    San, L.2    Duenas, R.M.3    Centeno, M.4    Ramirez, N.5    Salavert, J.6
  • 3
    • 77957129707 scopus 로고    scopus 로고
    • Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
    • Bitter I., Treuer T., Dilbaz N., Oyffe I., Ciorabai E.M., Gonzalez S.L., et al. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry 2010, 11:894-903.
    • (2010) World J Biol Psychiatry , vol.11 , pp. 894-903
    • Bitter, I.1    Treuer, T.2    Dilbaz, N.3    Oyffe, I.4    Ciorabai, E.M.5    Gonzalez, S.L.6
  • 4
    • 33846624634 scopus 로고    scopus 로고
    • Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS study
    • Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J., et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS study. Schizophr Res 2007, 90:162-173.
    • (2007) Schizophr Res , vol.90 , pp. 162-173
    • Bobes, J.1    Arango, C.2    Aranda, P.3    Carmena, R.4    Garcia-Garcia, M.5    Rejas, J.6
  • 5
    • 42549153837 scopus 로고    scopus 로고
    • Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial
    • Chawla B., Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Hum Psychopharmacol Clin Exp 2008, 23:211-216.
    • (2008) Hum Psychopharmacol Clin Exp , vol.23 , pp. 211-216
    • Chawla, B.1    Luxton-Andrew, H.2
  • 6
    • 35348992825 scopus 로고    scopus 로고
    • Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets
    • Crocq M.-A., Guillon M.-S., Bailey P.E., Provost D. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry 2007, 22:453-454.
    • (2007) Eur Psychiatry , vol.22 , pp. 453-454
    • Crocq, M.-A.1    Guillon, M.-S.2    Bailey, P.E.3    Provost, D.4
  • 7
    • 54849381700 scopus 로고    scopus 로고
    • Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
    • Daumit G.L., Goff D.C., Meyer J.M., Davis V.G., Nasrallah H.A., McEvoy J.P., et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008, 105:175-187.
    • (2008) Schizophr Res , vol.105 , pp. 175-187
    • Daumit, G.L.1    Goff, D.C.2    Meyer, J.M.3    Davis, V.G.4    Nasrallah, H.A.5    McEvoy, J.P.6
  • 8
    • 5444233534 scopus 로고    scopus 로고
    • Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets
    • De Haan L., van Amelsvoort T., Rosien K., Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004, 175:389-390.
    • (2004) Psychopharmacology , vol.175 , pp. 389-390
    • De Haan, L.1    van Amelsvoort, T.2    Rosien, K.3    Linszen, D.4
  • 9
  • 10
    • 42749096559 scopus 로고    scopus 로고
    • Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects
    • Graham K.A., Cho H., Brownley K.A., Harp J.B. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 2008, 101:287-294.
    • (2008) Schizophr Res , vol.101 , pp. 287-294
    • Graham, K.A.1    Cho, H.2    Brownley, K.A.3    Harp, J.B.4
  • 11
    • 0020535524 scopus 로고
    • A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity
    • Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
    • (1983) Psychol Med , vol.13 , pp. 177-183
    • Hogan, T.P.1    Awad, A.G.2    Eastwood, R.3
  • 13
    • 67650090764 scopus 로고    scopus 로고
    • A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS study
    • Karagianis J., Grossman L., Landry J., Reed V.A., de Haan L., Maguire G.A., et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS study. Schizophr Res 2009, 113:41-48.
    • (2009) Schizophr Res , vol.113 , pp. 41-48
    • Karagianis, J.1    Grossman, L.2    Landry, J.3    Reed, V.A.4    de Haan, L.5    Maguire, G.A.6
  • 15
    • 18844364769 scopus 로고    scopus 로고
    • Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders
    • Kinon B.J., Kaiser C.J., Ahmed S., Rotelli M.D., Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacology 2005, 25:255-258.
    • (2005) J Clin Psychopharmacology , vol.25 , pp. 255-258
    • Kinon, B.J.1    Kaiser, C.J.2    Ahmed, S.3    Rotelli, M.D.4    Kollack-Walker, S.5
  • 16
    • 0023244845 scopus 로고
    • The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients
    • Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987, 334(Suppl):1-100.
    • (1987) Acta Psychiatr Scand , vol.334 , Issue.SUPPL , pp. 1-100
    • Lingjaerde, O.1    Ahlfors, U.G.2    Bech, P.3    Dencker, S.J.4    Elgen, K.5
  • 17
    • 31344479789 scopus 로고    scopus 로고
    • Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers
    • Markowitz J.S., DeVane C.L., Malcolm R.J., Gefroh H.A., Wang J.-S., Zhu H.-J., et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacology 2006, 46:164-171.
    • (2006) J Clin Pharmacology , vol.46 , pp. 164-171
    • Markowitz, J.S.1    DeVane, C.L.2    Malcolm, R.J.3    Gefroh, H.A.4    Wang, J.-S.5    Zhu, H.-J.6
  • 18
    • 16644392426 scopus 로고    scopus 로고
    • Abnormalities of glucose metabolism associated with atypical antipsychotic drugs
    • Newcomer J.W. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004, 65(Suppl.18):36-46.
    • (2004) J Clin Psychiatry , vol.65 , Issue.SUPPL.18 , pp. 36-46
    • Newcomer, J.W.1
  • 19
    • 38349185038 scopus 로고    scopus 로고
    • Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol
    • Saddichha S., Ameen S., Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 2008, 28:27-31.
    • (2008) J Clin Psychopharmacol , vol.28 , pp. 27-31
    • Saddichha, S.1    Ameen, S.2    Akhtar, S.3
  • 20
    • 13544277253 scopus 로고    scopus 로고
    • Division of Mental Health and Protection of Substance Abuse. World Health Organization, Kanekoshobou, Tokyo, (in Japanese)
    • Tasaki M., Nakane M. WHO QOL 26 1997, Division of Mental Health and Protection of Substance Abuse. World Health Organization, Kanekoshobou, Tokyo, (in Japanese).
    • (1997) WHO QOL 26
    • Tasaki, M.1    Nakane, M.2
  • 21
    • 77957874979 scopus 로고    scopus 로고
    • Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study
    • Vidarsdottir S., Vlug P., Roelfsema F., Froelich M., Pijl H. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. J Clin Psychiatry 2010, 71:1205-1211.
    • (2010) J Clin Psychiatry , vol.71 , pp. 1205-1211
    • Vidarsdottir, S.1    Vlug, P.2    Roelfsema, F.3    Froelich, M.4    Pijl, H.5
  • 22
    • 73949102385 scopus 로고    scopus 로고
    • Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets
    • Vidarsdottir S., Roelfsema F., Streefland T., Holst J.J., Rehfeld J.F., Pijl H. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur J Endocrinology 2010, 162:75-83.
    • (2010) Eur J Endocrinology , vol.162 , pp. 75-83
    • Vidarsdottir, S.1    Roelfsema, F.2    Streefland, T.3    Holst, J.J.4    Rehfeld, J.F.5    Pijl, H.6
  • 23
    • 0031775905 scopus 로고    scopus 로고
    • Development of the World Health Organization WHOQOL-BREF: quality of life assessment
    • WHO-QOL group
    • Development of the World Health Organization WHOQOL-BREF: quality of life assessment. Psychol Med 1998, 28:551-558. WHO-QOL group.
    • (1998) Psychol Med , vol.28 , pp. 551-558


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.